SEMERÁD, Lukáš, Barbora WEINBERGEROVÁ, N. PODSTAVKOVÁ, Anežka KVETKOVÁ, Zuzana MRKVOVÁ, Jakub VOLDŘICH, Jiřina PROCHÁZKOVÁ, Ivana JEŽÍŠKOVÁ, A. FOLTA, Marek BORSKÝ, Marie JAROŠOVÁ and Jiří MAYER. Hodnocení minimální zbytkové choroby u nemocných s De Novo akutní myeloidní leukemií léčených kombinovanou terapií Azacitidine a Venetoclax. (Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.). In XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Hodnocení minimální zbytkové choroby u nemocných s De Novo akutní myeloidní leukemií léčených kombinovanou terapií Azacitidine a Venetoclax.
Name (in English) Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.
Authors SEMERÁD, Lukáš (203 Czech Republic, belonging to the institution), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), N. PODSTAVKOVÁ (203 Czech Republic), Anežka KVETKOVÁ (703 Slovakia, belonging to the institution), Zuzana MRKVOVÁ (203 Czech Republic, belonging to the institution), Jakub VOLDŘICH (203 Czech Republic, belonging to the institution), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), A. FOLTA, Marek BORSKÝ (203 Czech Republic, belonging to the institution), Marie JAROŠOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes, 2023.
Other information
Original language Czech
Type of outcome Conference abstract
Field of Study 30205 Hematology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/23:00131075
Organization unit Faculty of Medicine
Keywords in English acute myeloid leukemia; Azacitidine; Venetoclax
Tags rivok
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 13/3/2024 09:24.
Abstract
Hodnocení minimální zbytkové choroby u nemocných s De Novo akutní myeloidní leukemií léčených kombinovanou terapií Azacitidine a Venetoclax - konferenční abstrakt.
Abstract (in English)
Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy - conference abstract.
Links
LX22NPO5102, research and development projectName: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES
PrintDisplayed: 28/8/2024 02:55